Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.
Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...
Livewire Markets on MSN2d
The 4 biotech firms the experts are most excited aboutThe biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Zacks Investment Research on MSN2d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback